13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A mitochondrial switch promotes tumor metastasis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metastatic progression of cancer is associated with poor outcome, and here we examine metabolic changes underlying this process. Although aerobic glycolysis is known to promote metastasis, we have now identified a different switch primarily affecting mitochondria. The switch involves overload of the electron transport chain (ETC) with preserved mitochondrial functions but increased mitochondrial superoxide production. It provides a metastatic advantage phenocopied by partial ETC inhibition, another situation associated with enhanced superoxide production. Both cases involved protein tyrosine kinases Src and Pyk2 as downstream effectors. Thus, two different events, ETC overload and partial ETC inhibition, promote superoxide-dependent tumor cell migration, invasion, clonogenicity, and metastasis. Consequently, specific scavenging of mitochondrial superoxide with mitoTEMPO blocked tumor cell migration and prevented spontaneous tumor metastasis in murine and human tumor models.

          Related collections

          Author and article information

          Journal
          Cell Rep
          Cell reports
          2211-1247
          Aug 7 2014
          : 8
          : 3
          Affiliations
          [1 ] Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium.
          [2 ] Louvain Drug Research Institute (LDRI), Biomedical Magnetic Resonance Research Group (REMA), Université catholique de Louvain (UCL), Brussels 1200, Belgium.
          [3 ] URBC-NARILIS, University of Namur, Namur 5000, Belgium.
          [4 ] Institut de Recherche Expérimentale et Clinique (IREC), Pole of Pharmacology (FATH), Université catholique de Louvain (UCL), Brussels 1200, Belgium. Electronic address: pierre.sonveaux@uclouvain.be.
          Article
          S2211-1247(14)00527-0
          10.1016/j.celrep.2014.06.043
          25066121
          d00a7daf-a6ac-41d4-a1c5-687831c896d3
          Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article